**SUPPLEMENTARY MATERIAL**

# Efficacy and Safety of Secukinumab in US Patients With Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies

Alan J. Kivitz, MD, CPI,[1] Joel M. Kremer, MD, FACP,[2] Clarence W. Legerton III, MD,[3] Luminita Pricop, MD,[4] Atul Singhal, MD[5]

[1]Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, USA; [2]The Center for Rheumatology, Albany, NY, USA; [3]Low Country Rheumatology/Articularis Healthcare, North Charleston, SC, USA; [4]Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; [5]Southwest Rheumatology, Dallas, TX, USA

**Corresponding author:**

Alan J. Kivitz, MD, CPI,

Email: ajkivitz@yahoo.com

**Supplementary Table S1.** Baseline characteristics for US and non-US patients in the FUTURE 2-5 trials

| Characteristic | US (n = 279) | Non-US (n = 1770) |
|---|---|---|
| Age, mean (SD), years | 51.6 (12.6) | 48.5 (12.2) |
| Sex, n (%) | | |
| Male | 124 (44.4) | 851 (48.1) |
| Female | 155 (55.6) | 919 (51.9) |
| Race, n (%) | | |
| White | 256 (91.8) | 1576 (89.0) |
| Asian | 3 (1.1) | 129 (7.3) |
| Black or African American | 5 (1.8) | 2 (0.1) |
| American Indian or Alaska Native | 2 (0.7) | 12 (0.7) |
| Other | 12 (4.3) | 47 (2.7) |
| Unknown | 1 (0.4) | 3 (0.2) |
| Weight, mean (SD), kg | 92.0 (21.3) | 83.5 (18.7) |
| BMI, mean (SD), $kg/m^2$ | 32.3 (7.0) | 29.1 (5.9) |
| Time since PsA diagnosis, mean (SD), years | 7.0 (8.3) | 6.7 (7.5) |
| Prior TNFi therapies, n (%) | | |
| 0 | 125 (44.8) | 1311 (74.1) |
| 1 | 88 (31.5) | 266 (15.0) |
| ≥2 | 66 (23.7) | 193 (10.9) |
| Methotrexate use at randomization, n (%) | 83 (29.7) | 928 (52.4) |

| | | |
|---|---|---|
| Disease characteristics, n (%) | | |
| Psoriasis affecting ≥3% of BSA | 119 (42.7) | 898 (50.7) |
| Presence of enthesitis | 195 (69.9) | 1089 (61.5) |
| Presence of dactylitis | 108 (38.7) | 626 (35.4) |
| Disease and QOL scores, mean (SD) | | |
| TJC78 | 25.2 (17.8) | 20.6 (15.8) |
| SJC76 | 13.7 (11.7) | 10.5 (8.8) |
| DAS28-CRP score | 4.9 (1.1) | 4.6 (1.0) |
| HAQ-DI score | 1.2 (0.6) | 1.2 (0.6) |
| PsA pain, VAS 0-100 mm | 53.5 (23.4) | 55.0 (23.0) |
| Patient global assessment, VAS 0-100 mm | 55.5 (22.8) | 57.5 (21.5) |
| Physician global assessment, VAS 0-100 mm | 53.2 (17.9) | 55.6 (18.3) |

BMI, body mass index; BSA, body surface area; DAS28-CRP, Disease Activity Score 28-joint count using C-reactive protein; DAS28-ESR, Disease Activity Score 28-joint count using erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; LD, loading dose; PsA, psoriatic arthritis; QOL, quality of life; SJC76, swollen joint count of 76 joints; TJC78, tender joint count of 78 joints; TNFi, tumor necrosis factor inhibitor; VAS, visual analog scale.

**Supplementary Table S2.** Treatment-emergent adverse events up to Week 16 occurring in ≥3% of US patients

| | Secukinumab | | | Placebo |
|---|---|---|---|---|
| **Adverse events by patient, n (%)** | **300 mg (n = 72)** | **150 mg (n = 83)** | **150 mg, no LD (n = 34)** | **(n = 90)** |
| **Upper respiratory tract infection** | 4 (5.6) | 8 (9.6) | 3 (8.8) | 9 (10.0) |
| **Arthralgia** | 3 (4.2) | 1 (1.2) | 1 (2.9) | 2 (2.2) |
| **Cough** | 3 (4.2) | 2 (2.4) | 1 (2.9) | 1 (1.1) |
| **Hematuria** | 3 (4.2) | 0 | 1 (2.9) | 1 (1.1) |
| **Hypertension** | 3 (4.2) | 0 | 1 (2.9) | 5 (5.6) |
| **Oropharyngeal pain** | 3 (4.2) | 1 (1.2) | 1 (2.9) | 1 (1.1) |
| **Headache** | 2 (2.8) | 1 (1.2) | 0 | 5 (5.6) |
| **Sinusitis** | 2 (2.8) | 5 (6.0) | 1 (2.9) | 2 (2.2) |
| **Diarrhea** | 1 (1.4) | 3 (3.6) | 2 (5.9) | 0 |
| **Nasopharyngitis** | 1 (1.4) | 2 (2.4) | 3 (8.8) | 7 (7.8) |
| **Nausea** | 1 (1.4) | 6 (7.2) | 0 | 6 (6.7) |
| **Urinary tract infection** | 1 (1.4) | 3 (3.6) | 1 (2.9) | 3 (3.3) |
| **Fall** | 0 | 0 | 3 (8.8) | 1 (1.1) |
| **Hypercholesterolemia** | 0 | 3 (3.6) | 0 | 2 (2.2) |
| **Vomiting** | 0 | 3 (3.6) | 0 | 0 |

LD, loading dose.

**Supplementary Fig. S1** Study design.




LD, loading dose; PBO, placebo; SEC, secukinumab.

**Supplementary Fig. S2** Achievement of individual MDA components among US patients at Week 16.[a]




| No. of evaluable patients | SEC 300 mg | SEC 150 mg | SEC 150 mg NL | PBO |
|---|---|---|---|---|
| TJC78 ≤1 | 70 | 80 | 33 | 78 |
| SJC76 ≤1 | 70 | 80 | 33 | 78 |
| Tender/swollen sites ≤1 | 57 | 68 | 25 | 64 |
| HAQ-DI ≤0.50 | 57 | 68 | 25 | 64 |
| PsA pain ≤15 | 63 | 72 | 29 | 71 |
| Patient global assessment ≤20 | 60 | 74 | 30 | 72 |
| PASI ≤1 or BSA ≤3 | 43 | 47 | 20 | 45 |

BSA, body surface area; HAQ-DI, Health Assessment Questionnaire-Disability Index; MDA, minimal disease activity; PASI, Psoriasis Area and Severity Index; PBO, placebo; PsA, psoriatic arthritis; SEC, secukinumab; SJC76, swollen joint count of 76 joints; TJC78, tender joint count of 78 joints.

[a] In these radar plots, greater distance from the origin corresponds to a greater proportion of patients achieving clinical response.

[b] Among patients with count >1 at baseline.

[c] Among patients with baseline HAQ-DI >0.5.

[d] Among patients with baseline PsA pain >15.

[e] Among patients with baseline patient global assessment >20.

[f] Among patients with baseline PASI >1 or BSA >3%.

**Supplementary Fig. S3** Radiographic progression among US patients at Week 24 as determined by the proportion of patients with vdH-mTSS ≤0 and by mean change from baseline in vdH-mTSS.




PBO, placebo; SEC, secukinumab; vdH-mTSS, van der Heijde modified total Sharp score.

[a] Numbers of evaluable patients for each group at Week 24 are displayed above the x-axis.